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Abstract 
Background: Circulating microRNAs (miRs) are differentially regulated and selectively packaged into microparticles 
(MPs). We evaluated whether diabetes mellitus alters circulating vascular and endothelial MP-incorporated miRs 
expression levels.
Methods and results: Circulating MPs were isolated from 135 patients with or without diabetes mellitus type II 
and characterized using flow cytometer and electron microscope. Nine miRs involved in the regulation of vascular 
performance—miR-126, miR-222, miR-let7d, miR-21, miR-30, miR-92a, miR-139, miR-199a and miR-26a—were quanti-
fied in circulating MPs by reverse transcription polymerase chain reaction. Among those, miR-126 and miR-26a were 
significantly reduced in diabetic patients compared to non-diabetic patients. Patients with low miR-26a and miR-126 
levels were at higher risk for a concomitant coronary artery disease. MP-sorting experiments showed that endothelial 
cells were the major cell sources of MPs containing miR-126 and miR-26a, respectively. Finally, in accordance with our 
clinical results, in vitro experiments revealed that hyperglycemia reduces the packaging of miR-126 and miR-26a into 
EMPs.
Conclusion: Diabetes mellitus significantly alters the expression of vascular endothelial miRs in circulating endothe-
lial MPs with potential implications on vascular heath.
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Background
MicroRNAs (miRs) are small (22-nucleotide) noncoding 
RNAs regulating gene expression at the posttranscrip-
tional level by binding to the target mRNA, leading either 
to mRNA degradation or to translational repression [1]. 
miRs have emerged as key regulators of several physio-
logical and pathophysiological processes in cardiovascu-
lar (CV) and metabolic health and disease [2, 3]. Besides 
their intracellular function, recent studies have demon-
strated that miRs can be exported or released by cells 
and circulate in the blood in a remarkably stable form [4]. 
The discovery of circulating miRs opens up fascinating 
possibilities to use circulating miR patterns as biomark-
ers for CV and metabolic diseases [5, 6]. Altered levels 
of circulating miRs have been reported in patients with 
heart failure, coronary artery disease (CAD), and diabe-
tes [7–9].
Recent findings have emerged that microparticles (MPs) 
represent major protective transport vehicles for miRs by 
separating them from circulating ribonuclease (RNase) [10]. 
Moreover, increasing evidence suggests that MP-associated 
miRs not only represent passively released cellular debris, 
but may also contribute to intercellular signaling mecha-
nisms [11]. In this context, we and others have demon-
strated that endothelial cell-derived MPs mediate vascular 
protection and endothelial regeneration in a miR-126-de-
pendent mechanism [12, 13]. Importantly, previous data 
revealed that the biological content and functional effect of 
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MPs depends on the condition of the releasing cell. Hyper-
glycemic conditions in  vitro significantly changed miRs 
expression levels in MPs and subsequently altered their bio-
logical effect on target cells [12, 14]. Taken together, these 
findings suggest that circulating MP-packaged miRs, in 
addition to their function as biomarkers, represent func-
tional mediators in vascular and metabolic diseases.
Diabetes mellitus is characterized by increased blood 
glucose levels and represents a major risk factor for car-
diovascular morbidity and mortality. As a consequence of 
endothelial activation and dysfunction, diabetic patients 
show increased plasma level of circulating MPs [15]. 
Moreover, elevated levels of circulating EMPs are asso-
ciated with vascular dysfunction in diabetic patients and 
MPs derived from hyperglycemic cells fostered athero-
genesis, suggesting an active role of MPs in diabetic com-
plications [16, 17].
Several studies showed promising results for the use 
of circulating miRs as potential biomarker in diabetic 
patients. However, whether diabetes mellitus is associated 
with changes in miRs expression pattern in circulating 
MPs is unknown. As miR-containing MPs regulate vascu-
lar function and disease progression, a detailed exploration 
of miRs expression in circulating MPs in patients with and 
without diabetes would be of high interest to understand 
the pathogenesis of vascular complications in diabetic 
patients and develop novel therapies opportunities.
In a translational approach, we first describe that diabe-
tes mellitus alters vascular miRs expression levels in cir-
culating MPs. These findings provide novel evidence for a 
potential role of miR-containing MPs in the regulation of 
vascular integrity in patients with diabetes mellitus.
Methods
Study subjects
Between August 2012 and July 2013, 141 patients pre-
senting in our outpatient department were screened for 
inclusion in the study. Six patients with clinical presen-
tation of acute or subacute myocardial infarction were 
excluded from the study. Patients with malignant, inflam-
matory diseases, or severe hepatic or renal dysfunction 
were also excluded from the study. Informed consent 
was obtained from all patients and the ethics committee 
of the University of Bonn approved the study protocol. 
Based on previous medical reports, patients were either 
grouped in the diabetes mellitus group (DM, n  =  55) 
or the non-diabetic group (NDM group, n  =  80). All 
patients included in DM group took either oral antidia-
betic drugs or used subcutaneous insulin application.
Preparation of blood samples
Venous blood was drawn under sterile conditions from 
the cubital vein and was buffered using sodium citrate 
(for MPs quantification) or ethylenediaminetetraacetic 
acid (EDTA, for miR analysis). Additional blood samples 
for routine analyses were obtained. Blood was centri-
fuged at 1500g for 15  min followed by centrifugation at 
13,000g for 2  min to generate platelet-deficient plasma. 
The deprived plasma samples were immediately stored in 
−80  °C. Annexin V/CD 31 positive microparticles level 
were measured freshly with flow cytometry by using 
Annexin V-FITC and CD31-PE (BD Pharmingen). Plate-
let-deficient plasma was stored in −80 °C until miR level 
were analyzed.
Microparticles collection and RNA isolation
RNA was isolated from circulating MPs by using TRI-
zol-based miR isolation protocol. 250  μl total plasma 
was centrifuged at 20,000g for 30  min at 4  °C to pellet 
circulating MPs as previously described [18]. The pellet 
was diluted in 250 μl RNase-free water and then diluted 
in 750 μl TRIzol® LS in order to measure MPs miRs lev-
els. Caenorhabditis elegans miR-39 (cel-miR-39, 5  nM, 
Qiagen) was spiked in TRIzol for normalization of miR 
content as described [19]. To increase the yield of small 
RNAs, the RNA was precipitated in ethanol at −20  °C 
overnight with glycogen (Invitrogen).
Sorting of microparticles subspecies
For sorting of MPs subspecies, 250  µl platelet-free 
plasma was stained with CD31-PE, and CD42b-APC (BD 
Pharmingen) and the corresponding isotype and nega-
tive controls. Stained plasma was incubated for 45 min in 
dark at room temperature according to the manufactures 
suggestions.
To sort MPs subspecies, a FACSAria™ III Flow Cytom-
eter (BD Biosciences) was used. Vesicles between 100–
1000  nm in diameter were gated for sorting. CD31+/
CD42b−, CD31+/CD42b+ and CD31−/CD42b− MPs 
were gated, sorted and collected as shown in Additional 
file  1. RNAse-free water was added to the sorted MPs 
to reach a total volume of 250  μl, which was diluted in 
750 μl TRIzol® LS in order to measure MPs miRs levels. 
C. elegans miR-39 (cel-miR-39, 5 nM, Qiagen) was spiked 
in TRIzol for normalization of miRs content as described 
[20]. To increase the yield of small RNAs, the RNA was 
precipitated in ethanol at −20 °C overnight with glycogen 
(Invitrogen).
Quantification of miRs by quantitative PCR
RNA was quantified using Nanodrop spectrophotometer 
(Nanodrop Technologies Inc). 10  ng of the total RNA 
was reversely transcribed using TaqMan® microRNA 
reverse transcription kit (Applied Biosystems) accord-
ing to the manufactures protocol. miR-126, miR-222, 
miR-let7d, miR-21, miR-30, miR-92a, miR-139, miR-199a 
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and miR-26a in circulating MPs were detected by using 
TaqMan® microRNA assays (Applied Biosystems) on a 
7500 HT Real-Time PCR machine (Applied Biosystems). 
Cel-miR-39 was used as an endogenous control. For all 
miRs, a Ct value above 40 was defined as undetectable. 
Delta Ct method was used to quantify relative microRNA 
expression. Values were normalized to cel-miR-39 and 
are expressed as 2−ddct log 10. For all PCR experiments, 
samples were run in triplicates.
Cell culture and endothelial microparticles generation
Human coronary artery endothelial cells (HCAEC, Pro-
moCell) were cultured in endothelial cell growth media 
with endothelial growth media Supplement Mix (Pro-
mocell) under standard cell culture conditions (37  °C, 
5 % CO2). Cells of passage 4–7 were used when 70–80 % 
confluent. Endothelial microparticles (EMPs) were gen-
erated from HCAEC as previously described with minor 
changes [21]. Briefly, confluent cells were starved by 
subjecting to basal media without growth media sup-
plements for 24 h to induce apoptosis. After starvation, 
supernatant of apoptotic HCAEC was collected and cen-
trifuged at 1500g for 15  min to remove cell debris. The 
supernatant was centrifuged (20,000g, 40  min) to pellet 
EMPs. The obtained EMPs were washed in sterile phos-
phate buffered saline (PBS, pH 7.4) and pelleted again 
at 20,000g for 40  min. In order to generate EMPs from 
endothelial cells under hyperglycemic conditions, conflu-
ent HCAEC were stimulated with 30 mM glucose for 72 h 
[22] and then subjected to basal media without growth 
media supplements for 24 h to generate EMPs. Micropar-
ticles derived from glucose-treated endothelial cells were 
defined as “high glucose” EMPs (hgEMPs). Pelleted EMPs 
were resuspended in sterile PBS and used freshly.
Electron microscope
MPs were isolated using 20,000g ultracentrifugation as 
described previously [20]. The obtained pellet was fixed 
in 3  % glutaraldehyde PBS overnight at 4  °C. The pel-
let was then washed with 0.1 M cacodylate buffer, post-
fixed in 2 % OsO4, washed again with 0.1 M cacodylate 
buffer and dehydrated in graded ethanol. The sample 
was embedded in Epon-pur and 50  nm sections were 
prepared on copper grids. Samples were visualized on a 
Philips CM 10 electronic microscope and analyzed with 
analySiS software (Olympus).
Flow cytometry analysis on EMPs
In vitro generated and pelleted EMPs were suspended in 
100 µl annexin V-binding buffer (10 mM HEPES, pH 7.4, 
140 mM NaCl, 2.5 mM CaCl2) with and without calcium 
as control. 5  µl annexin V-FITC (BD Biosciences) was 
added. After incubation for 15 min at room temperature, 
diluted EMPs were centrifuged for 20  min at 20,000g, 
washed with sterile PBS and re-centrifuged. The pelleted 
EMPs were resuspended in 100  µl annexin V-binding 
buffer and 4  µl CD31-PE (BD Biosciences) or isotype 
control was added. After incubation for 30 min at room 
temperature, diluted EMPs were centrifuged and washed 
as described above. Pelleted EMPs were resuspended in 
200 µl annexin V-binding buffer and analyzed with FACS 
BD LSR II. To evaluate the size of EMPs, the following 
fluorescent reference beads were used: nile red particles 
0.7–0.9 µm (Spherotech), nile red particles 2 µm (Sphero-
tech), BD Calibrate 3 Beads 6 µm (BD Biosciences).
MicroRNA expression in vitro
Total RNA was isolated out of EMPs, hgEMPs, HCAEC 
and hgHCAEC by TRIzol (Invitrogen) extraction method 
according to instruction of the manufacturer. To increase 
the yield of small RNAs, the RNA is precipitated in etha-
nol at −20 °C overnight with glycogen (Invitrogen). RNA 
is quantified using Nanodrop spectrophotometer. Then, 
10  ng of the total RNA was reversely transcribed using 
TaqMan® microRNA reverse transcription kit (Applied 
Biosystems) according to the manufacturers protocol. 
Taqman microRNA assays (Applied Biosystems) were 
used to measure miR-126 and miR-26a levels on a 7500 
HT Real-Time PCR machine (Applied Biosystems). RNU-
6b was used as an endogenous control. Delta Ct method 
was used to quantify relative microRNA expression.
Statistical analysis
Continuous variables were tested for normal distribu-
tion with Kolmogorov–Smirnov test. Normally distrib-
uted continuous variables were presented as mean ± SD. 
Mann–Whitney U test was used to analyze variables with 
skewed distribution. Means between two categories were 
compared with the two-tailed, unpaired Student’s t test. 
The Chi square test was used for categorical data that 
result from classifying objects. Binary logistic regression 
was applied to identify factors that were independently 
associated with miR-126 and miR-26a. Statistical signifi-
cance was assumed when the null hypothesis could be 
rejected at p  <  0.05. Statistical analysis was performed 
with IBM SPSS Statistics version 20 (USA).
Results
Baseline characteristics
A total of 135 patients with (DM, n  =  55) or without 
diabetes mellitus (NDM, n  =  80) were enrolled in the 
study. There was no difference regarding age and sex 
between the groups. DM patients had more frequently a 
concomitant arterial hypertension (p =  0.024), a higher 
body mass index (p = 0.001) and coronary artery disease 
(p = 0.009). Regarding the medication, DM patients took 
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more frequently calcium channel blockers (p = 0.019). As 
expected, DM patients had higher fasting blood glucose 
levels (p = 0.0001) and higher HbA1c values (p = 0.0001). 
DM patients showed reduced HDL (p = 0.009) and LDL 
(p = 0.03) levels. Furthermore, DM was associated with a 
significantly higher number of circulating annexin V-pos-
itive MPs (p = 0.014, Table 1).
miR selection and detection in circulating MPs.
Table 1 Baseline characteristics of the study population
Continuous data are expressed as mean ± standard deviation and categorical data are expressed as frequencies. Chronic kidney disease was defined as a glomerular 
filtration rate <60 mL/min
DM diabetes mellitus, NDM non diabetes mellitus, CAD coronary artery disease, MI myocardial infarction, ACE angiotensin-converting enzyme, LDL low-density 
lipoprotein, HDL high-density lipoprotein, MP microparticle
Italic values indicate significance of p value (p < 0.05)
Characteristic Total (n = 135) DM (n = 55) NDM (n = 80) p value
Age in years 66.4 ± 10.9 67.6 ± 10.6 65.5 ± 11.1 0.279
Gender no. (%) 0.711
 Female 45 (33.3 %) 17 (30.9 %) 28 (35 %)
 Male 90 (66.7 %) 38 (69.1 %) 52 (65 %)
Cardiovascular risk factors no. (%)
 Arterial hypertension 110 (81.5 %) 50 (90.9 %) 60 (75 %) 0.024
 Hyperlipoproteinemia 71 (52.6 %) 29 (52.7 %) 42 (52.5 %) 0.979
 Family history of CAD 40 (29.6 %) 14 (25.5 %) 16 (20 %) 0.529
 Smoking 29 (21.5 %) 10 (18.2 %) 19 (23.8 %) 0.525
 Body mass index kg/m2 28.4 ± 5.2 30.5 ± 5.4 26.9 ± 4.5 0.001
Medical history no. (%)
 Previous MI (6 months) 40 (29.6 %) 16 (29.1 %) 24 (30 %) 0.910
 Previous bypass 15 (11.1 %) 8 (14.5 %) 7 (8.8 %) 0.404
 Previous stroke 7 (5.2 %) 3 (5.5 %) 4 (5 %) 0.907
 Chronic kidney disease 4 (3.0 %) 2 (3.6 %) 2 (2.5 %) 0.702
Coronary artery disease no. (%) 0.009
 3 vessels 49 (36.3 %) 24 (44.4 %) 25 (31.7 %)
 2 vessels 37 (27.4 %) 20 (37.0 %) 17 (21.5 %)
 1 vessel 15 (11.1 %) 3 (5.6 %) 12 (15.2 %)
 Left ventricular ejection fraction  (%) 57.2 ± 12.2 60.0 ± 12.8 57.4 ± 11.8 0.831
Medication on admission no. (%)
 ACE inhibitors 85 (63.0 %) 35 (63.6 %) 50 (62.5 %) 0.893
 Angiotensin receptor blockers 29 (21.5 %) 13 (23.6 %) 16 (20 %) 0.672
 Beta blockers 115 (85.2 %) 45 (81.8 %) 70 (87.5 %) 0.461
 Calcium channel blockers 28 (20.7 %) 17 (30.9 %) 11 (13.8 %) 0.019
 Diuretics 62 (45.9 %) 27 (49.1 %) 35 (43.8 %) 0.600
 Statins 109 (80.7 %) 45 (81.8 %) 64 (80 %) 0.828
 Nitrates 5 (3.7 %) 1 (1.8 %) 4 (5 %) 0.648
 Aspirin 115 (85.2 %) 47 (85.5 %) 58 (72.5 %) 0.093
Laboratory parameters
 Glucose mg/dL 126.4 ± 58.6 167.1 ± 72.3 99.0 ± 19.2 0.0001
 HbA1c (%) 6.4 ± 1.0 7.2 ± 1.2 5.9 ± 0.4 0.0001
 Serum creatinine mg/dL 0.98 ± 0.33 1.01 ± 0.33 0.97 ± 0.32 0.645
 Glomerular filtration rate mL/min 65.1 ± 11.0 64.3 ± 12.4 65.7 ± 9.9 0.463
 Triglycerides mg/dL 166.2 ± 204.5 199.4 ± 302.8 144.4 ± 84.2 0.137
 Cholesterol mg/dL 184.645 ± 48.8 173.2 ± 44.6 192.5 ± 50.2 0.023
 HDL cholesterol mg/dL 49.9 ± 17.7 45.2 ± 16.6 53.2 ± 17.8 0.009
 LDL cholesterol mg/dL 110.3 ± 37.3 102.0 ± 34.2 116.0 ± 38.4 0.030
 C-reactive protein mg/L 4.4 ± 6.5 4.5 ± 5.8 4.3 ± 7.0 0.826
 Leucocytes 109/L 7.3 ± 2.1 7.3 ± 1.7 7.2 ± 2.3 0.807
 Concentration of Annexin V + MP/µl 778.72 ± 1439.4 1144.0 ± 1849.4 526.2 ± 1009.1 0.014
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Nine vascular and endothelial cell–expressed miRs that 
have been shown to be involved in the pathogenesis of 
diabetes mellitus were chosen to compare their expres-
sion levels in DM and NDM patients: miR-126, miR-222, 
miR-let7d, miR-21, miR-30, miR-92a, miR-139, miR-199a 
and miR-26a. Because previous studies strongly suggest 
that circulating miRs are selectively packaged into MPs, 
levels of analyzed miRs were measured in circulating 
MPs in all patients.
Circulating microparticles characterization
Isolated MPs were characterized regarding their size 
using electron microscopy and flow cytometer. Charac-
terization experiments revealed that the vast majority of 
isolated MPs had a size between 0.1 and 1 µm in diam-
eter (Fig. 1a, b).
miR expression in circulating MPs in DM and NDM 
patients.
Analysis of miR expression pattern in isolated MPs 
from DM and NDM patients showed no difference in 
miR-222, miR-let7d, miR-21, miR-30, miR-92a, miR-139 
and miR-199a. In contrast, miR-26a and miR-126 were 
significantly reduced in DM patients compared to NDM 
patients (Fig. 2).
Comorbidities such as hypertension and CAD or medi-
cation affect circulating miR levels. Binary logistic regres-
sion analysis demonstrated that changes in expression 
levels of miR-126 and miR-26a were associated with a 
concomitant CAD, but independent of other comorbidi-
ties. Regarding medication intake, there was a significant 
association of miR-126 levels and statin intake, whereas 
miR-126 and miR-26a levels were independent of all 
other drugs (Tables  2, 3). To explore the association of 
miR-26a and miR-126 expression with the occurrence of 
a concomitant CAD, we categorized the study population 
into two groups according to the median of miR-26a and 
miR-126 expression. Importantly, patients with reduced 
miR-26a and miR-126 expression levels were at higher 
risk for the occurrence of a concomitant CAD (Table 4).
Endothelial MPs are the major source for circulating 
MP‑bound miR‑126 and miR‑26
Because circulating MPs compose different subspecies 
of membrane particles released from endothelium and 
blood cells, we sorted endothelial-, platelet-, and other 
cell-derived MPs using flow cytometer to explore the 
cellular origins of MP-bound miR-126 and miR-26a in 
DM patients. Overall, miR-126 and miR-26a showed the 
highest expression in CD31+/CD42b− endothelial cell-
derived MPs, compared to CD31+/CD42b+ platelet-
derived MPs and annexin V+/CD31−/CD42b− MPs 
(Fig. 3).
To explore whether CD31+/CD42b− MPs are the 
major source for other endothelial miRs as well, two other 
endothelial miRs—namely miR-199a and miR-let7d—
were additionally analyzed in different MPs subsets. In 
contrast to miR-126 and miR-26a, RT-PCR experiments 
revealed no significant differences in miR-199a and miR-
let7d expression in different MPs subsets, suggesting 
that miR-126 and miR-26a are selectively packaged into 
endothelial cell-derived MPs (Additional file 1).
Hyperglycemia in vitro reduces endothelial 
MP‑incorporated miR‑126 and miR‑26a expression
As MP-bound miR-126 and miR-26a were significantly 
reduced in DM patients and endothelial cell-derived 
MPs were shown to be the major source of miR-126 and 
miR-26-containing MPs, we finally explored the effect of 
hyperglycemic conditions in vitro on miRs expression on 
endothelial cells and endothelial MPs. In accordance with 
the clinical data, hyperglycemia significantly reduced the 
expression of miR-126 and miR-26a in endothelial cell-
derived MPs without affecting the cellular level (Fig. 4).
Analysis of other endothelial miRs (miR-21, miR-30, 
miR-92a, miR-139, miR-222) revealed that hyperglyce-
mia additionally, besides miR-26a and miR-126, reduced 
expression of miR-222, whereas expression of other miRs 
were not affected (Additional file 1).
Taken together, we provide evidence that diabetes 
mellitus affects circulating MP-incorporated vascular 
Fig. 1 Circulating MPs characterization. a Circulating MPs were 
collected by 20,000g ultracentrifugation of platelet-deficient plasma. 
Fluorescent polystyrene particles (0.7–0.9, 2 and 6 µm) were used to 
evaluate the size of isolated MPs. In flow cytometer, analyzed MPs 
(red) had a size <1 μm as demonstrated using fluorescent polystyrene 
particles. b The obtained pellet after 20,000g ultracentrifugation was 
fixed in 3 % glutaraldehyde PBS overnight at 4 °C and embedded in 
Epon-pur. 50 nm sections were prepared on copper grids. Samples 
were visualized on a Philips CM 10 electronic microscope and ana-
lyzed with analySiS software (Olympus)
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endothelial miRs expression level with potential implica-
tions for vascular health.
Discussion
miRs are powerful regulators of cellular processes. 
Moreover, an increasing number of studies demonstrate 
that miRs can be detected in circulating blood and that 
these circulating miRs might be useful biomarkers in 
patients with metabolic diseases such as diabetes melli-
tus. Circulating MPs represent major transport vehicles 
for miRs by separating them from circulating RNase. 
Moreover, DM patients show elevated levels of circu-
lating MPs, which might be actively involved in the 
progression of vascular dysfunction in diabetic condi-
tions [16, 17]. However, so far the biological content of 
circulating MPs in patients with or without DM is vastly 
unknown.
Role of miR‑126 and miR‑26a in vascular biology
In this study, we found that DM is associated with 
reduced endothelial miR-126 and miR-26a expression 
in circulating MPs. Previous clinical studies pointed out 
a potential implication of miR-126 in the context of car-
diovascular and metabolic diseases. Analysis of circu-
lating miRs in patients with CAD showed significantly 
reduced levels of miR-126 in patients with CAD in com-
parison with healthy controls [19]. Furthermore, plasma 
miRs profiling revealed a significant loss of miR-126 in 
patients with diabetes mellitus [9]. In circulating angio-





















































































































Fig. 2 miRs expression in circulating MPs in DM and NDM patients. Delta Ct method was used to quantify relative microRNA expression. Values 
were normalized to cel-miR-39 and are expressed as 2−[CT(microRNA)−CT(cel–miR−39)] log10
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mononuclear cells, intracellular miR-126 expression 
defined their regenerative capacity and was reduced in 
diabetic patients [23, 24]. Own data showed that patients 
Table 2 Association of  miR-26a levels with  baseline char-
acteristics
The coefficient of the continuous variables was relative to 1-U differences. Binary 
logistic regression according to the median of miR-26a level
Exp(B) exponentiation of the B coefficient, miR microRNA
Italic value indicates significance of p value (p < 0.05)
Exp(B) (95 % CI) p value
Age 0.981 (0.932–1.033) 0.465
Male sex 1.306 (0.409–4.174) 0.652
Body mass index 1.062 (0.950–1.186) 0.291
Coronary artery disease 2.320 (1.047–5.138) 0.038
Arterial hypertension 0.632 (0.205–1.953) 0.426
Hyperlipoproteinemia 1.179 (0.445–3.123) 0.740
Smoking 0.808 (0.247–2.641) 0.725
Chronic kidney disease 1.101 (0.081–14.961) 0.943
Angiotensin Converting Enzyme  
Inhibitors (ACEI)
1.404 (0.440–4.482) 0.566
Angiotensin receptor blockers (ARB) 0.970 (0.269–3.495) 0.963
Calcium channel blockers (CCB) 1.566 (0.565–4.339) 0.389
Diuretics 0.551 (0.252–1.205) 0.135
Statins 0.615 (0.185–2.037) 0.426
Nitrates 1.492 (0.215–10.347) 0.685
Aspirin 0.664 (0.196–2.248) 0.510
Clopidogrel 0.675 (0.293–1.558) 0.358
Table 3 Association of  miR-126 levels with  baseline char-
acteristics
The coefficient of the continuous variables was relative to 1-U differences. Binary 
logistic regression according to the median of miR-126 level
Exp(B) exponentiation of the B coefficient, miR microRNA
Italic values indicate significance of p value (p < 0.05)
Exp(B) (95 % CI) p value
Age 0.981(0.937–1.026) 0.402
Male sex 1.480 (0.534–4.101) 0.451
Body mass index 1.031 (0.963–1.102) 0.381
Coronary artery disease 2.444 (1.086–5.051) 0.031
Arterial hypertension 0.410 (0.133–1.266) 0.121
Hyperlipoproteinemia 0.831 (0.354–1.953) 0.671
Smoking 1.227 (0.411–3.667) 0.714
Chronic kidney disease 1.393 (0.106–18.389) 0.801
Angiotensin converting enzyme  
inhibitors (ACEI)
0.803 (0.241–2.682) 0.722
Angiotensin receptor blockers (ARB) 0.634 (0.166–2.423) 0.505
Calcium channel blockers (CCB) 1.237 (0.462–3.310) 0.673
Diuretics 0.501 (0.227–1.103) 0.086
Statins 0.158 (0.040–0.632) 0.009
Nitrates 3.256 (0.263–40.306) 0.358
Aspirin 2.075 (0.550–7.825) 0.281
Clopidogrel 0.681 (0.295–1.573) 0.368
Table 4 Lower miR-26a and miR-126 levels are associated 
with the occurrence of coronary artery disease
Low level below the median, high level above the median, CAD coronary artery 
disease, miR microRNA
low level (n = 62) high level (n = 63) p value
miR-26a
 No CAD (n = 37) 13 24 0.049
 CAD (n = 88) 49 39
low level (n = 63) high level (n = 63) p value
miR-126
 No CAD (n = 35) 12 23 0.046
 CAD (n = 91) 51 40














Fig. 3 Analysis of microRNA in microparticle subspecies. Endothelial 
cell–derived (CD31+/CD42b−), platelet-derived (CD31+/CD42b+), 
and other cell–derived MPs (CD31−/CD42b−) were from 10 plasma 
samples of DM patients, and miR-126 and miR-26a expression were 
analyzed in MPs subspecies. **p < 0.01, n = 10. Relative quantification 
of miR expression was determined using the comparative CT method 
[2−ddCT, internal control: Cel-miR−39]. MPs indicate microparticles























Fig. 4 Hyperglycemia reduces miR-126 and miR-26a level in hgEMPs. 
miR-126 and miR-26a were was analyzed in ECs, hgECs, EMPs and 
hgEMPs. RNU6b served as endogenous control. *p < 0.05, n = 5–6
Page 8 of 10Jansen et al. Cardiovasc Diabetol  (2016) 15:49 
with stable coronary artery disease and diabetes mellitus 
express reduced levels of circulating MP-bound miR-126 
compared to non-diabetic patients [12]. Additional exper-
iments revealed that miR-126-containing endothelial cell-
derived MPs promoted vascular regeneration, which was 
abrogated in MPs collected under hyperglycaemic condi-
tions [12]. These findings strongly indicate a crucial role 
for miR-transporting MPs in the regulation of vascular 
health, which is altered under diabetic conditions. Fur-
thermore, we found that MP-bound miR-222 was reduced 
in endothelial cell-derived MPs under hyperglycaemic 
conditions [14]. However, in the present study, there was 
no difference in circulating miR-222 levels between DM 
and NDM patients. These findings suggest that freely cir-
culating miRs levels and MP-bound miRs can be regu-
lated independently and differently in diabetic conditions.
miR-26a is expressed, besides others, in endothe-
lial cells and has been shown to prevent endothelial cell 
apoptosis by directly targeting TRPC6 in atherosclerotic 
mice [25]. In the setting of diabetes, it has been recently 
shown that liver-specific miR-26a plays a crucial role in 
the regulation of insulin sensitivity and glucose metabo-
lism in obese mice and human. Of note, similar to our 
findings, miR-26a expression was significantly reduced 
in obese human and mice compared to healthy controls 
[26]. Given that miR-26a inhibits endothelial apoptosis, 
and miR-containing MPs can affect target cell biology, 
one may speculate that MPs with low miR-26a expres-
sion levels as occurring in diabetic patients might have 
a reduced protective effect on target cells. Impaired 
angiogenesis is one main microangiopathic complica-
tion in patients with diabetes mellitus. In this context, 
miR-26a has been shown to regulate pathological and 
physiological angiogenesis by targeting BMP/SMAD1-
signaling. Inhibition of miR-26a induced robust angio-
genesis within 2 days, an effect associated with reduced 
myocardial infarct size and improved heart function [27].
Our data show that MP-incorporated miR-26a expres-
sion is reduced in patients with DM. Based on these find-
ings and the before mentioned publication, one would 
suggest that lower levels of miR-26a in circulating MPs in 
DM patients would rather promote angiogenesis in tar-
get cells. If this comes true, this could be a compensatory 
mechanism from endothelial cells to release MPs with a 
proangiogenic message as an attempt to decelerate DM-
associated impairment of angiogenesis.
MP-sorting experiments showed that endothelial cells 
were found to be the major cell sources of MPs con-
taining miR-126 and miR-26a in diabetic patients. In 
accordance with these data, circulating MP-bound miR-
126 was mainly expressed in circulating endothelial 
cell-derived MPs in patients with stable coronary artery 
disease, whereas miR-199a was primarily detectable in 
platelet-derived MPs [20]. However, another study found 
platelets as major contributor to circulating miR-126 sig-
natures in patients with acute myocardial infarction [28]. 
These differences might be due to diverse patients collec-
tives, different pathological conditions and/or variances 
in the used MPs isolation and miRs analysis protocols.
Extracellular vesicles‑incorporated miRs in intercellular 
communication
Circulating miRs in plasma can be transported within 
extracellular vesicles (exosomes, MPs, apoptotic bodies) 
[29] or bound to proteins (high-density lipoprotein, Ago-
2) [30, 31]. Both routes provide remarkable stability and 
resistance to degradation from endogenous RNase activity. 
Previously, we found that endothelial cell-derived miR-126 
and miR-199a were mainly expressed in circulating MPs, 
whereas miR-222, miR-21, miR-27, and miR-92a were 
detectable mainly in vesicle-free plasma. As MP-bound 
miRs, compared to freely circulating miRs, were shown 
to predict cardiovascular events in patients with stable 
coronary artery disease [32], we focused on analyzing 
the expression of MP-bound miRs in this study. A selec-
tive packaging of miRs into different plasma sub compart-
ments was recently shown by Wang et al., who compared 
profiles of miRs in cell-derived vesicles (i.e., exosomes and 
MPs) with vesicle-free miRs (i.e., supernatant fraction after 
ultracentrifugation) and found that miRs profiles within 
and outside these vesicles were strikingly different [33].
The notion that miRs selectively packaged into MPs 
may play a crucial role in intercellular signaling is sup-
ported by an increasing experimental data [11, 34]. In 
this context, injected miRs containing apoptotic bod-
ies were shown to be transported into atherosclerotic 
lesions, where they controlled the downstream target 
CXCL12 and promoted vascular protection. Further-
more, Hergenreider et  al. described an atheroprotective 
communication mechanism between endothelial cells 
and vascular smooth muscle cells via endothelial cell-
derived exosomes in a miR-143/145-dependent way. 
Taken together, these well-performed and convincing 
studies demonstrated the cardioprotective potential of 
intercellular communication mechanisms by miR-con-
taining extracellular vesicles [13, 34].
Our study broaden these findings by demonstrating 
that not only cardiovascular, but also metabolic disor-
ders like diabetes mellitus alter the expression of vascular 
miRs in circulating MPs.
Of note, miRs expression in diabetic vasculopathy is 
regulated by diverse factors. In this context, vitamin D 
has been described as important issue manipulating miRs 
expression in diabetic vasculopathy [35]. Furthermore, 
miR-1 and miR-208a were regulated dependent on the gen-
der of examined mice in a model of streptozotocin-induced 
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diabetes [36]. Diabetes and hyperlipidemia-induced inflam-
matory responses can upregulate the expression of con-
nexins and Rho kinase by selective downregulation of 
the expression of miR-10a, miR-139b, miR-206, and miR-
222 [37]. Exploration of circulating miRs as a biomarker 
revealed, in the setting of acute heart failure, that low circu-
lating levels of miR-423-5p at presentation were associated 
with a poor long-term outcome [38]. Importantly, miRs can 
target several genes. That can be associated with undesired 
‘off-target’ side effects, which has to be taken into consid-
eration in general in miRs research [39].
Limitations
This study has limitations. Only a selected number of 
miRs, based on previously published data, were ana-
lyzed. Moreover, although there is profound knowledge 
concerning the function of endothelial miR-126, the 
role of vascular miR-26a in diabetic conditions is largely 
unknown. Further exploration of MPs derived under nor-
mal and hyperglycaemic conditions containing different 
miR-26a levels is of importance to understand their role 
on vascular biology. Regarding the patients characteriza-
tion, we did not prospectively collect the data for dura-
tion of all DM patients and can not give exact data on 
disease duration for DM patients.
In addition, exploration of selection and packaging 
mechanisms of miRs into MPs would be of interest to 
better comprehend the physiological and pathophysi-
ological functions of miR-containing MPs in metabolic 
and vascular biology. Furthermore, the analysis of circu-
lating miRs bound to other cargos than miRs (e.g. HDL 
or Ago proteins) would be of interest for future studies. 
Finally, the relatively small sample size limits the final 
conclusion that can be drawn from this study.
Conclusions
Taken together, we show that diabetes mellitus signifi-
cantly alters the expression of vascular endothelial miRs 
in circulating endothelial MPs with potential implica-
tions on vascular heath.
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